What happened: first patient treated in ICECAP for vulnerable coronary plaque CryoTherapeutics has treated the first patient in the multicenter ICECAP clinical trial, a study evaluating whether targeted localized cryotherapy can stabilize vulnerable, non-obstructive coronary plaques before they rupture and cause myocardial infarction. The company said the first enrolled patient presented with stable angina and was found, during screening, to have a non-obstructive high-risk plaque. CryoTherapeutics, based in Liège, Belgium, is developing a catheter-based system that delivers focal cooling between -10 and -20 degrees Celsius to selected coronary lesions. The device is investigational and has not been approved or cleared for commercial use in any jurisdiction. ## How patients and plaques are identified: a multimodal, AI-enabled workflow ICECAP uses a layered imaging strategy to find and treat plaques that may not produce significant stenosis on traditional angiography. Patients are screened with coronary CT imaging combined with AI-enabled plaque characterization tools to flag lesions that exhibit high-risk features. During the treatment procedure, intravascular imaging is employed to confirm plaque morphology and guide the catheter. The study uses near-infrared spectroscopy (NIRS) and optical coherence tomography (OCT) for intravascular confirmation and positioning. Follow-up imaging is planned to quantify biological changes over time, including measures such as fibroatheroma cap thickness. ## Why this approach matters: addressing plaques that often escape detection The trial responds to a growing recognition that many myocardial infarctions arise from plaques that were not significantly obstructive beforehand. The source notes that roughly half of heart attacks are estimated to stem from such plaques, which can rupture without warning despite not producing major flow limitation on angiography. That epidemiology has spurred interest in technologies that improve detection of vulnerable lesions before they cause events. ICECAP couples noninvasive coronary CT angiography and machine learning-based risk stratification with invasive intravascular imaging to both identify and treat high-risk plaques in a single workflow. ## The investigational therapy: localized cryotherapy and its intended effect CryoTherapeutics’ catheter system applies localized cooling to target plaques. The company’s stated aim in ICECAP is to determine whether that cooling can induce changes in plaque biology—such as stabilizing fibroatheroma caps—that would reduce the risk of rupture-driven myocardial infarction. The specific temperature range cited for delivered cooling is between -10 and -20 degrees Celsius. The trial will monitor plaques over time with repeat imaging to assess the biological response to the cryotherapy intervention. Details such as the number of patients planned, primary and secondary endpoints, or timelines for results were not reported in the source article. ## Collaboration and trial sites ICECAP is supported by a multidisciplinary group of clinical, imaging and data science collaborators. Named partners include the Cardiovascular Research Foundation, HeartFlow and Medis Medical Imaging. These organizations contribute expertise in intravascular imaging, coronary CT analysis, quantitative image analysis and AI-assisted plaque assessment. Patient recruitment is currently active and the study is expected to expand to as many as five centers across Belgium and the United Kingdom in the coming months, according to CryoTherapeutics. ## The broader trend in cardiology and device development Interventional cardiology is increasingly focused on disease that does not present as an obvious blockage on angiography. Device manufacturers and imaging companies have invested in tools to detect and characterize soft, high-risk plaques that may not yet narrow a vessel. This shift moves care upstream from treating obstructive lesions to attempting to prevent events by identifying and intervening on vulnerable plaques. ICECAP is one of several early-stage efforts exploring whether a targeted therapy can work in tandem with advanced imaging and AI-based risk stratification to lower heart attack rates tied to previously undetected disease. The source emphasizes that whether localized cryotherapy will prove effective remains to be seen and will depend on results from ICECAP and similar studies. ## Quotes from study leaders and company John Yianni, CEO of CryoTherapeutics, said treating the first patient in ICECAP is an important milestone for the company and its clinical development. Carlos Collet, director of cardiovascular imaging, physiology and translational therapeutics at the Cardiovascular Research Foundation, described the study as combining state-of-the-art plaque assessment with a novel therapy to stabilize vulnerable plaques. ## What’s next: enrollment and evidence generation The company reported active recruitment and plans to broaden enrollment to multiple centers in Belgium and the U.K. The ICECAP workflow includes baseline coronary CT with AI-based screening, intravascular confirmation of high-risk morphology with NIRS and OCT at the time of treatment, and longitudinal imaging to measure plaque response. Specific outcome timelines and detailed trial endpoints were not provided in the source. Ultimately, evidence from ICECAP and related early-stage trials will determine whether localized cryotherapy can become a validated option for preventing myocardial infarction caused by non-obstructive vulnerable plaques.